Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 33369 - uncoated unicondylar knee femur prosthesis - the sigma hp partial femorals are uncoated unicondylar femoral replacements, made out of cocr and for cemented use. they articulate with one of the sigma hp partial inserts. the sigma hp partial femoral is one component of the sigma high performance partial knee system and is intended to provide increased patient mobility and reduced pain by replacing the damaged knee joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. the sigma high performance partial knee system is indicated for single compartmental knee replacement in skeletally mature individuals with osteoarthritis, post-traumatic arthritis of the tibiofemoral surfaces or a history of gout or pseudogout. the sigma hp partial femorals are intended for cemented use only.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 34195 - unicondylar knee prosthesis - the sigma hp partial uni tibial tray is a unicondylar tibial tray manufactured from cocr. it has a metal back and is intended for cemented use. an appropriately sized cross-linked polyethylene insert is held in place with a locking mechanism. the sigma hp partial uni tibial tray is the tibial component of the sigma high performance partial knee system and is intended to provide increased patient mobility and reduced pain by replacing the damaged knee joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. the sigma high performance partial knee system is indicated for single compartmental knee replacement in skeletally mature individuals with osteoarthritis, post-traumatic arthritis of the tibiofemoral articular surfaces or a history of gout or pseudogout. intended for cemented use only.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 33369 - uncoated unicondylar knee femur prosthesis - the sigma hp partial femorals are uncoated unicondylar femoral replacements, made out of cocr and for cemented use. they articulate with one of the sigma hp partial inserts. the sigma hp partial femoral is one component of the sigma high performance partial knee system and is intended to provide increased patient mobility and reduced pain by replacing the damaged knee joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. the sigma high performance partial knee system is indicated for single compartmental knee replacement in skeletally mature individuals with osteoarthritis, post-traumatic arthritis of the tibiofemoral articular surfaces or a history of gout or pseudogout. the sigma hp partial femorals are intended for cemented use only.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 46585 - prosthesis, knee, internal, insert component - the sigma rp-f tibial inserts are manufactured from uhmwpe and reinforced with astm f-90 co-cr-mo alloy pins. the sigma rp-f tibial inserts articulate with the sigma rp-f femoral component and m.b.t. primary and revision trays. the sigma rp-f tibial inserts are part of the lcs complete ? p.f.c. sigma rp mobile bearing total knee system and are indicated for use in cases of osteoarthritis and rheumatoid arthritis. the sigma rp-f inserts are indicated where a higher than normal degree of post-operative flexion is required.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 32831 - uncoated knee femur prosthesis - the sigma cr150 femur is made from cobalt chromium and is a high flexion variant of the pfc sigma total knee replacement system. it makes available a femoral component that provides additional stability during high knee flexion (beyond 120?). the sigma cr 150 knee provides stability in cr femoral components by providing congruent contact of the posterior femoral condyles with the tibial insert at up to 150? of flexion. the sigma cr150 femur is one component of a total or unicompartmental knee arthroplasty which is intended to provide increased patient mobility and reduced pain by replacing the damaged knee joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. total or unicompartmental knee replacement may be considered for younger patients if, in the opinion of the surgeon, an unequivocal indication for total or unicompartmental knee replacement outweighs the risks associated with the age of the patient, and if limited demands regarding activity and knee joint loading can be assured. this includes severely crippled patients with multiple joint involvement for whom a gain in knee mobility may lead to an expectation of significant improvement in the quality of their lives.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hydrocortisone acetate -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hydrocortisone acetate -

Spojené štáty - angličtina - NLM (National Library of Medicine)

sigmapharm laboratories, llc - acitretin (unii: lch760e9t7) (acitretin - unii:lch760e9t7) - acitretin 10 mg - acitretin capsules, usp are indicated for the treatment of severe psoriasis in adults. because of significant adverse effects associated with its use, acitretin capsules, usp should be prescribed only by those knowledgeable in the systemic use of retinoids. in females of reproductive potential, acitretin capsules, usp should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed contraindications and warnings — acitretin capsules, usp can cause severe birth defects). most patients experience relapse of psoriasis after discontinuing therapy. subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. pregnancy category x:  ( see boxed contraindications and warnings. ) acitretin is con

Spojené štáty - angličtina - NLM (National Library of Medicine)

sigmapharm laboratories, llc - protriptyline hydrochloride (unii: 44665v00o8) (protriptyline - unii:4ndu154t12) - protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. its activating properties make it particularly suitable for withdrawn and anergic patients. protriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with a monoamine oxidase inhibiting compound. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. protriptyline is contraindicated in patients taking cisapride because of the possibility of adverse cardiac interaction

Spojené štáty - angličtina - NLM (National Library of Medicine)

sigmapharm laboratories, llc - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide is contraindicated in patients with congenital or acquired long qt syndromes. dof